Abnormal Pap in Pregnancy Alexander Burnett, MD Division Gyn Oncology, UAMS April, 2006.

Slides:



Advertisements
Similar presentations
HPV Testing and Genotyping
Advertisements

CERVICAL CANCER... Diagnosis & Treatment.
MANAGEMENT OF ABNORMAL PAP SMEAR
In the name of God Isfahan medical school Shahnaz Aram MD.
MANAGEMENT OF THE ABNORMAL PAP SMEAR
Cervical Cancer. Dr. Swapna Chaudhary M.S. (MUM) Consultant Obstetrician & Gynaecologist Infertility Specialist.
Cervical Cancer DR KHALID H. WALI SAIT (FRCSC) ASSOCIATE PROFESSOR OF GYNECOLOGICAL ONCOLOGY King Abdulaziz University Hospital, Jeddah, Saudi Arabia.
Cervical Cancer American Cancer Society Georgia Department of Human Resources The University of Georgia Cooperative Extension Service.
Gynaecological Cancers
Updates on Pap Smear Guidelines 2014
Speaker: Decca Mohammed, MD.  Statistics for cervical cancer and HPV  Association of HPV to cervical cancer, and other cancers  Prevention  Screening.
Evolution of Neoplasia The Uterine Cervix As a Model Raj C. Dash, MD Duke University Medical Center Durham, North Carolina.
ASHLYN SAVAGE, MD, MSCR ASSOCIATE PROFESSOR OBSTETRICS AND GYNECOLOGY MEDICAL UNIVERSITY OF SOUTH CAROLINA Managing Abnormal Pap Smears: Incorporating.
Sample Taker Training Cervical Cytology & Management of Abnormalities.
Cervix Dr. Raid Jastania. Cervical Cancer Screening HPV infection Pre- Cancerous Dysplasia Cancer years.
Cervical Cancer Cervical dysplasia Cervical cancer Causes Risk factors
Benign Conditions Of The Cervix Dr. Abdalla H. Elsadig MD.
ENHANCING DETECTION.... YOUR PRACTICE.
Screening for Cervical Cancer
Management of Women with CIN 1 or LSIL
Benign and premalignant disease of the cervix
Cervical Cancer Source: SEER’s Training Web Site
Cervical Cancer: Prevention and Treatment
Jacqueline Castagno, MD FACOG Division of Gynecologic Oncology Department of Obstetrics and Gynecology University of Florida College of Medicine.
Interim Guidance for the Use of Human Papillomavirus DNA Testing as an Adjunct to Cervical Cytology for Screening Obstetrics and Gynecology, Volume 103,
 Cervical cancer is a malignant tumour deriving from cells of the "cervix uteri", which is the lower part of uterus.  Begins in the lining of the cervix.
wrong to say cervical erosion -this condition appear at ( puberty ) ( pregnancy )
Case Presentations: Pre-Invasive Cervical Neoplasia
COLPOSCOPY Cervical Screening QARC Training School October 2012.
AN AUDIT OF PAP SMEAR, COLPOSCOPY AND HISTOLOGY RESULTS FROM IN TUNGARU CENTRAL HOSPITAL (KIRIBATI)
Cytopathology: Technique and Interpretation
Management of Gynaecological Cancers. Gynaecological Cancers in NSW 1180 new cases in % of all new cancer diagnoses Crude incidence rate 35.3 per.
Cervical Cancer Screening
Review of the Guidelines for Cervical Screening in New Zealand Presentation for smear-takers September 2008.
Cervical Cancer. Cervix Lower part of the uterus Lower part of the uterus Connects the body of the uterus to the vagina (birth canal) Connects the body.
Screening for Cervical Cancer by Visual Inspection Techniques Dr Aruna Batra VMMC & SJH.
CANCER CERVIX A PREVENTABLE CANCER Dr NEETA DHABHAI Sr Consultant. – Gynaecologist Member Expert - Indian Cancer Winners’ Association
การบริหารจัดการโครงการวิจัย ภาควิชาสูติศาสตร์และนรีเวช วิทยา 5 เมษายน 2550 ห้องประชุม A 501 ชั้น 5 อาคารบริหาร คณะแพทยศาสตร์ ม. สงขลานครินทร์
Screening for Cervical Cancer Max Brinsmead MB BS PhD May 2015.
Cancer of Cervix Shashi. Sep-15 Introduction: Best example of cancer prevention. Best example of cancer prevention. Potentially curable if detected early.
SoftPAP® A Novel Collection Device for Cervical Cytology.
Screening for cervical cancer. Screening for cervical lesions Common disease Cancer is preventable Screening is easy MUST BE PERFORMED.
Copyright © 2005, Duke Internal Medicine Residency Curriculum and DHTS Technology Education Services Duke Internal Medicine Residency Curriculum Screening.
In the Name of God. Screening of Cervical Cancer Pap smear and colposcopy F.Behnamfar Gynecology Oncology Fellowship Associate Professor Isfahan University.
Cervical Intraepithelial Neoplasm
Cancer of Cervix Shashi. Oct-15 Introduction: Best example of cancer prevention. Best example of cancer prevention. US Statistics: US Statistics: Leading.
KATIE OSTROM PAPS, ABORTION, AND VACUUM DELIVERY.
Adult Medical-Surgical Nursing
Cervical Cancer Screening Guidelines Update
Cytologic Findings in Type 2 Cervical Carcinomas: Some Cervical Carcinomas are more Difficult to Prevent with Screening R. Marshall Austin MD,PhD Magee-Womens.
Premalignant lesions of the cervix. Applied anatomy.
Screening of genital cancers Evidence Based Presented by Dr\ Heba Nour.
CERVICAL SCREENING ANGELIKA KAUFMANN, ST4, UHCW, MEDICAL STUDENT INDUCTION, 2015.
COLPOSCOPY QUESTIONS Michael R. Downs M.D. October 2004.
2006 ASCCP Consensus Guidelines Anne L. Kittendorf, MD FAAFP Assistant Professor University of Michigan Department of Family Medicine.
Cytopathology Feb
Dr. Ahmed Jasim.  About 1% in pregnant women  It is formed of fibers and muscle of uterus and can be submucous, interstitial, or subserous.
Cervical Cancer Screening NURS 541: Women’s Healthcare – Diagnosis and Management.
Cervical Screening: Do I Really Need a Pap Test April 2010.
Trreatment of Preinvasive Lesions
Cervical Cancer Colposcopy & Treatment
Dr N Shailaja Dr Pradeep
Updates on Pap Smear Guidelines 2014
AGC&AIS Setareh Akhavan M.D Gynecologist Oncologist
What is a Pap smear? A Pap smear (also known as the Pap test) is a medical procedure in which a sample of cells from a woman's cervix (the end of the uterus that.
SH-sheikhhasani Gyn-oncologist
Presentation transcript:

Abnormal Pap in Pregnancy Alexander Burnett, MD Division Gyn Oncology, UAMS April, 2006

Objectives 1. Significance of Pap smears during pregnancy 2. Problems with Pap smears 3. Management of abnormal results 4. Treatment during pregnancy 5. Post-partum evaluation

Pap smear is part of prenatal testing  Screening opportunity  Cervical cancer is the most common malignancy detected in pregnancy (1-15/10,000)  Majority of cancer patients are stage I -- 83%  CIS detected in ~1/750 pregnancies

Cytology during pregnancy Technique: Cervical brush for LBM Ayre spatula + cytobrush Cotton swab is inadequate Endocervical component absent in 55% of Paps that utilized cotton swabs

Pregnancy effects on Pap  0.5% - 3.0% of Paps abnormal  Mimics of HSIL: Degenerated decidual cells Cytotrophoblast Arias-Stella reaction (confuse with adenocarcinoma) Immature reactive metaplasia  Mimics of LSIL:Syncytiotrophoblast Multinucleated cells

Management of abnormal Pap  Identical to non-pregnant patient  Indications for colposcopy: HSILLSILASC-H ASCUS + HPV AGUS Suspicion for cancer  ECC is never indicated during pregnancy!

Colposcopic challenges  Vaginal laxity  Cervical laxity  Inadequate visualization of TZ  Increased vascularity of cervix  Increased squamous metaplasia

Frequency of colposcopy  Recommended each trimester for visual inspection of dysplasia  Inadequate transformation zone will often become adequate with cervical eversion over gestation  “Clearance” for delivery  No need to repeat the Pap smear at each colposcopy

Biopsy in pregnancy  Should be performed for suspicion of HSIL or invasive disease  Directed biopsy with immediate application of pressure, silver nitrate, and/or Monsel’s  Safe to perform at any stage in pregnancy  Do not repeat biopsy at later colposcopy unless significant change is seen

Cone biopsy  Indicated if biopsy suggests microinvasion  Associated with increased bleeding (> 500 cc in 10%), preterm labor, infection, spontaneous abortion in first trimester.  LEEP can be performed, similar complications reported as cold-knife  ONLY done in surgical suite setting

Management of SIL in pregnancy  Pre-invasive disease should not be treated in pregnancy  Repeat colposcopy to follow patient with biopsy if a significant change is noted  Re-evaluate in the post-partum period (at least 6-8 weeks)

Cervical cancer in pregnancy  Pregnancy does not appear to significantly alter the course of disease  Management is based on gestational age at time of diagnosis: < 20 weekstreat as non-pregnant > 24 weeksawait fetal viability weeksindividualize

Pre-viable treatment  Early cervix cancer: Radical hysterectomy with nodes Radiation therapy/chemotherapy  Late cervix cancer: Chemoradiation

Later pregnancy therapy  Document fetal maturity  Deliver via classical C/S  Radical hysterectomy at time of C/S

Planned delay in therapy  Numerous reports of patient opting for delays  Follow closely, increased bleeding risk  Chemotherapy has been utilized in rapidly growing cervix cancers  Outcome generally good, but numbers are small  Deliver via C/S

Dysplasia management  Delivery route should be for obstetric indications  Several reports have suggested high rate of regression post-partum, particularly if a vaginal delivery has occurred  6-8 weeks post-partum, reasonable to perform PAP, colposcopy, biopsies and ECC

Other management considerations  If colposcopy is difficult or suspicious for HSIL or microinvasion, consider referral to expert colposcopist to determine need for biopsy  Vascular lesions with negative Pap smears, consider referral, close monitoring to determine if this is dysplastic/malignant versus physiologic

Condylomas during pregnancy  Can rapidly grow during gestation  Increased risk of trauma at delivery  Increased risk of Respiratory Papillomatosis in offspring. Not prevented by C/S or wart therapy  Treatment: TCA, cryo for small lesions Cautery, LEEP, laser for large areas